Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK

Cardiovascular Drugs and Therapy

Volumn 20, Issue 1, 2006, Pages 13-25

  Moolman, Johannes A ^a   Hartley, Shahiem ^b   Van Wyk, Johanna ^b   Marais, Erna ^b   Lochner, Amanda ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b NONE

Author keywords

Adrenergic; Apoptosis; Ischaemic preconditioning; Necrosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANISOMYCIN; BETA ADRENERGIC RECEPTOR; CASPASE 3; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TETRAZOLIUM;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANISOMYCIN; APOPTOSIS; ENZYME ACTIVATORS; IMIDAZOLES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOPROTERENOL; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS;

EID: 33646471816     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-6257-7     Document Type: Article

References (42)

1. Gottlieb RRA, Engler RL. Apoptosis in myocardial ischemia-reperfusion. Ann NY Acad Sci 1999;874:412-426.
2. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000;32:197-208.
3. Krijnen PAJ, Nijmeijer R, Meijer CJLM, Hack CA, Niessen HWM. Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 2002;55:801-811.
4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal injury in ischemic myocardium. Circulation 1986;74:1124-1136.
5. Miura T, Ishimoto R, Sakamoto J, et al. Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: Is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor? Basic Res Cardiol 1995;90:240-246.
6. Nakamura M, Wang NP, Zhao ZQ, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat hearts. Cardiovasc Res 2000;45:661-670.
7. Piot CA, Padmanabam D, Ursell PC, Sievers RE, Wolfe CL. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 1997;96:1598-1604.
8. Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002;55:438-455.
9. Ambrosio G, Zweier JL, Becker LC. Apoptosis is prevented by administration of superoxide dismutase in dogs with reperfused myocardial infarction. Basic Res Cardiol 1998;93:94-96.
10. Freude B, Masters TN, Kostin S, Robicsek F, Schaper J. Cardiomyocyte apoptosis in acute and chronic conditions. Basic Res Cardiol 1998;93:85-89.
11. Maulik N, Engelman RM, Rousou JA, Flack JE III, Deaton D, Das DK. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 1999;100(19 Suppl):II369-II375.
12. Piot CA, Martini JF, Bui SK, Wolfe CL. Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly (ADP-ribose) polymerase in rat hearts in vivo. Cardiovasc Res 1999;44:536-542.
13. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol 2004;286:H246-H251.
14. Okamura T, Miura T, Iwamoto H, et al. Ischemic preconditioning attenuates apoptosis through protein kinase C in rat hearts. Am J Physiol 1999;277:H1997-H2001.
15. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-160.
16. Yin T, Sandhu G, Wolfgang CD, et al. Tissue-specific patterns of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997;272:19943-19950.
17. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-1691.
18. Han H, Wang H, Long H, Nattel S, Wang Z. Oxidative preconditioning and apoptosis in L-cells. Roles of protein kinase B and mitogen-activated protein kinases. J Biol Chem 2001;276:26357-26364.
19. Zhang S, Ren J, Zhang CE, Treskov I, Wang Y, Muslin AJ. Role of 14-3-3-mediated p38 mitogen-activated protein kinase inhibition in cardiac myocyte survival. Circ Res 2003;93:1026-1028.
20. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 2002;97:276-285.
21. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA. Activation of p38 MAPK induced by a multi-cycle ischaemic reconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Moll Cell Cardiol 2001;33:769-778.
22. Schneiders S, Chen W, Hou J, Steenbergen C, Murphy E. Inhibition of p38 MAPK a/b reduces ischemic injury and does not block the protective effects of preconditioning. Am J Physiol 2001;280:H499-H580.
23. Lochner A, Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA. Ischemic and pharmacological preconditioning is associated with attenuation of p38 MAPK activation during sustained ischemia and reperfusion. In: Dhalla NS, Takeda N, Lukas A, eds. Myocardial Ischemia and Preconditioning. Boston: Kluwer Academic Publishers, 2002:249-273.
24. Marais E, Genade S, Strijdom JG, Moolman JA, Lochner A. p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning. J Moll Cell Cardiol 2001;33:2157-2177.
25. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-1151.
26. McCully JD, Wakiyama H, Hsieh Y, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H1923-H1935.
27. Martin JL, Avkiram M, Quinlan RA, Cohen P, Marber MS. Anti-ischemic effects of SB203580 are mediated through the inhibition of p38 alpha mitogen-activated protein kinase: Evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 2001;89:750-752.
28. Otsu K, Yamashita N, Nishida K, et al. Disruption of a single copy of the p38alpha MAP kinase gene leads to cardioprotection against ischemia/ reperfusion. Biochem Biophys Res Commun 2003;302:56-60.
29. Clerk A, Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/cJun N-terminal kinases (SAPKs/JNKs). FEBS Lett 1998;426:93-96.
30. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: Infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003;98:337-346.
31. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997;96:4343-4348.
32. 2+/calmodulin kinase II. J Clin Invest 2003;111:617-625.
33. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 2001;98:1607-1612.
34. Tong H, Bernstein D, Murphy E, Steenbergen C. The role of β-adrenergic receptor signaling in cardioprotection. FASEB J 2005;19(8):983-985.
35. Frances C, Nazeyrollas P, Prevost P, et al. Role of beta-1 and beta-2 adrenoreceptor subtypes in preconditioning against myocardial dysfunction after ischaemia and reperfusion. J Cardiovasc Pharmacol 2003;41(3):396-405.
36. Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation 1999;100:958-966.
37. Barancik M, Htun P, Schaper W. Okadaic acid and anisomycin are protective and stimulate the SAPK/JNK pathway. J Cardiovasc Pharmacol 1999;34:182-190.
38. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 1999;274:6272-6279.
39. Lochner A, Genade S, Hattingh S, Marais E, Huisamen B, Moolman JA. Comparison between ischaemic and anisomycin-induced preconditioning: Role of p38 MAPK. Cardiovasc Drugs Ther 2003;17(3):217-230.
40. Martindale JJ, Wall JA, Martinez-Longoria DM, et al. Overexpression of mitogen-activated protein kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. JBC 2005;280(1):669-676.
41. Tanno M, Bassi R, Gorog DA, et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation. Circ Res 2003;93:254-261.
42. Zhu L, Fukuda S, Cordis G, Das DK, Maulik N. Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 2001;23,508(3):369-374.